Key facts
- It has raised $13.8M across 1 recorded rounds; the latest was Seed Round ($1.1M) in Mar 2026.
- Notable investors include Western Technology Investment, ATMA Capital, Biostack Ventures, Longevitytech.fund, Raiz Capital — 7 tracked in total.
- Yuva Biosciences has filed 1 Form D with the SEC, most recently Nov 2023 ( sold).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Yuva Biosciences
Funding rounds
1 roundsAbout Yuva Biosciences
Developer of artificial intelligence-driven compound discovery platforms intended for improving mitochondrial function and addressing cellular aging. The company's platform uses a proprietary AI system trained on experimental data to identify and validate small molecules that influence mitochondrial activity, supports research through in-house and partner-generated datasets, enables integration into cosmetic and therapeutic applications, and provides licensable compounds for formulation into skin and hair-related products, enabling biotechnology and consumer health markets to develop products targeting age-related cellular decline and energy metabolism dysfunction.
- Sector
- Healthcare
- HQ
- Birmingham, AL, United States
- Founded
- 2019
- Employees
- 7
- Website
- yuvabio.com/
- Ownership
- Privately Held (backing)
Yuva Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yuva Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yuva Biosciences in its N-PORT filings yet. We sweep new filings monthly.